Oncology

Featured

Videos

Zilurgisertib Alone or Combined With Ruxolitinib Well-Tolerated Among Patients With Myelofibrosis

07/25/2024

Prithviraj Bose, MD, shares results from an ongoing study that demonstrate that zilurgisertib as monotherapy or in combination with ruxolitinib had a favorable tolerance profile among patients with myelofibrosis.

Prithviraj Bose, MD, shares...

07/25/2024

Oncology

Conference Coverage

CAR T-Cell Therapy as New Standard of Care for Patients With Early Relapsed Large B-Cell Lymphoma

07/23/2024

Jason Westin, MD, shares expert insight regarding CAR T-cell therapy as standard of care treatment for patients with early relapsed large B-cell lymphoma at the 2024 Pan Pacific Lymphoma Conference.

Jason Westin, MD, shares expert...

07/23/2024

Oncology

Aditi Shastri, MD, Montefiore Einstein Comprehensive Cancer Center

Videos

How I Treat: An Elderly Patient With Lower-Risk, Ringed Sideroblastic Negative MDS

07/17/2024

Aditi Shastri, MD, discusses the treatment regimen she chose for an older patient with lower-risk, ringed sideroblastic negative myelodysplastic syndrome.

Aditi Shastri, MD, discusses the...

07/17/2024

Oncology

Videos

Examining Real-World Outcomes Among Patients With Myelofibrosis Treated With Pacritinib

07/17/2024

John Mascarenhas, MD, shares results of a retrospective study on the real-world treatment outcomes among patients with myelofibrosis who were treated with pacritinib.

John Mascarenhas, MD, shares...

07/17/2024

Oncology

Conference Coverage

Analyzing Evolution and Difference in the Latest Classifications of Lymphoma

07/16/2024

At the 2024 Pan Pacific Lymphoma Conference, Elaine Jaffe, MD, analyzes the differing classification systems of lymphoma, focusing on diffuse large B-cell lymphoma, follicular lymphoma, and small B-cell neoplasms.

At the 2024 Pan Pacific Lymphoma...

07/16/2024

Oncology

Conference Coverage

Potential Role of Dose-Adjusted EPOCH-R in the Frontline Setting Among Patients With Aggressive B-Cell Lymphomas

07/15/2024

Mark Roschewski, MD, shared expert insight on the possible role of dose-adjusted EPOCH-R as first-line treatment for patients with aggressive B-cell lymphomas.

Mark Roschewski, MD, shared...

07/15/2024

Oncology

Videos

How I Treat: An Older Patient With High-Risk CLL With Deletion 17p

07/15/2024

John Allan, MD, discusses the treatment regimen he chose for an older patient with high-risk chronic lymphocytic leukemia with deletion 17p who has chronic medical issues such as atrial fibrillation and diabetes.

John Allan, MD, discusses the...

07/15/2024

Oncology

Claire Harrison, MD, FRCP, Guy’s and St. Thomas’ NHS Foundation Trust

Q&As

Elritercept Well-Tolerated, Demonstrates Potential Efficacy for the Treatment of Patients With Myelofibrosis

07/11/2024

Claire Harrison, MD, FRCP, shares results of the ongoing phase 2 RESTORE trial in which elritercept was generally well-tolerated and demonstrated potential efficacy for treating patients with myelofibrosis.

Claire Harrison, MD, FRCP,...

07/11/2024

Oncology

Julie Vose, MD, University of Nebraska Medical Center

Videos

Optimizing Epcoritamab Therapy to Reduce CRS and ICANS Among Patients With R/R Follicular Lymphoma

07/09/2024

Julie Vose, MD, presents data from an optimization cohort that demonstrated improved safety of optimized epcoritamab treatment to strategically reduce CRS and ICANS among patients with R/R follicular lymphoma in the outpatient setting.

Julie Vose, MD, presents data...

07/09/2024

Oncology

Conference Coverage

Teclistamab Plus Daratumumab and Lenalidomide Show Manageable Safety, Early Efficacy as Frontline Therapy for Patients With Transplant-Ineligible MM

07/02/2024

At the 2024 ASCO Annual Meeting, Salomon Manier, MD, PhD, discusses data on teclistamab in combination with daratumumab and lenalidomide (DR) vs DR and dexamethasone as frontline therapy for patients with MM ineligible for transplant.

At the 2024 ASCO Annual Meeting,...

07/02/2024

Oncology

Conference Coverage

Nivolumab Plus Ipilimumab As Potential New Frontline Option for Patients With Unresectable Hepatocellular Carcinoma

07/02/2024

Peter Galle, MD, PhD, discussed results from the CheckMate 9DW trial which identified nivolumab plus ipilimumab as a potential new first-line option for patients with previously untreated, unresectable hepatocellular carcinoma.

Peter Galle, MD, PhD, discussed...

07/02/2024

Oncology

https://www.hmpgloballearningnetwork.com/site/onc-app

Insights From the ESMO Congress

Conference Coverage

Relatlimab Added to Nivolumab Has Robust Anti-Tumor Activity in Advanced Melanoma

11/22/2023

Stephanie Holland

Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.

Biomarker analyses from patients...

11/22/2023

Oncology

Quiz

Tisotumab Vedotin for Cervical Cancer

11/21/2023

Oncology

Conference Coverage

Avelumab Plus Cetuximab for Advanced Cutaneous Squamous Cell Carcinoma

11/20/2023

Featuring Juergen C. Becker, MD, PhD

Featuring Juergen C. Becker, MD, PhD ...

Juergen C. Becker, MD, PhD, German Cancer Consortium, discusses preliminary findings from the phase 2 AliCe study combining avelumab with cetuximab for patients with advanced, unresectable cutaneous squamous cell carcinoma.

Juergen C. Becker, MD, PhD,...

11/20/2023

Oncology

Arlene Siefker-Radtke, MD, MD Anderson Cancer Center

Videos

Erdafitinib Shows Similar OS to Pembrolizumab Among Patients With FGFR-Altered Advanced/Metastatic Urothelial Carcinoma

11/16/2023

Featuring Arlene Seifker-Radtke, MD

Featuring Arlene Seifker-Radtke, MD ...

Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.

Arlene Siefker-Radtke, MD,...

11/16/2023

Oncology

Videos

Using Liquid Biopsy to Guide Post-Surgical Treatment Among Patients With Colon Cancer

11/16/2023

Featuring Sara Lonardi, MD

Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.

Sara Lonardi, MD, shares results...

11/16/2023

Oncology

Kohei Shitara, MD, PhD, National Cancer Center Hospital East

Videos

Perioperative Pembrolizumab Plus Chemotherapy for Resectable Gastric or Gastroesophageal Junction Cancer

11/14/2023

Featuring Kohei Shitara, MD, PhD

Featuring Kohei Shitara, MD, PhD ...

In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.

In the KEYNOTE-585 study,...

11/14/2023

Oncology

Quiz

Adjuvant Radiotherapy Following Radical Prostatectomy

11/13/2023

Allison Casey

Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.

Test your knowledge on the...

11/13/2023

Oncology

Conference Coverage

Static and Dynamic Biomarkers to Optimize Adjuvant Therapy in Luminal Early Breast Cancer

11/10/2023

Featuring Oleg Gluz, MD

Oleg Gluz, MD, Evangelical Bethesda Hospital, Breast Center Niederrhein, Mönchengladbach, Germany, discusses results from the prospective WSG-ADAPT HR+/HER- trial.

Oleg Gluz, MD, Evangelical...

11/10/2023

Oncology

News

Adjuvant Radiotherapy Provided No Benefit Among Patients With Prostate Cancer Post-Radical Prostatectomy

11/10/2023

Allison Casey

Results from the phase 3 RADICALS-RT trial found there was no meaningful benefit derived from adjuvant radiotherapy following radical prostatectomy for patients with prostate cancer.

Results from the phase 3...

11/10/2023

Oncology

News

Niraparib Plus Abiraterone Acetate and Prednisone for BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer

11/10/2023

Allison Casey

Niraparib plus abiraterone acetate and prednisone improved several outcomes measures, including overall survival, among patients with BRCA-mutant metastatic castration-resistant prostate cancer.

Niraparib plus abiraterone...

11/10/2023

Oncology

Insights From the ASCO Annual Meeting

Conference Coverage

Sequencing Vemurafenib, Cobimetinib, and Atezolizumab for Patients With High-Risk Melanoma

07/22/2024

Paolo Ascierto, MD, discusses primary results from the phase 2 NEO-TIM trial which assessed the best sequencing of vemurafenib, cobimetinib, and atezolizumab among patients with high-risk melanoma.

Paolo Ascierto, MD, discusses...

07/22/2024

Oncology

Conference Coverage

Durvalumab as Standard-of-Care Consolidation Treatment for Patients With Limited-Stage Small-Cell Lung Cancer

07/19/2024

David Spigel, MD, discusses the results from phase 3 ADRIATIC trial, evaluating durvalumab with or without tremelimumab as consolidation treatment for patients with limited-stage small-cell lung cancer.

David Spigel, MD, discusses the...

07/19/2024

Oncology

Conference Coverage

Regorafenib Plus Pembrolizumab Among Patients With Advanced Hepatocellular Carcinoma Previously Exposed to Immunotherapy

07/18/2024

Anthony El-Khoueiry, MD, describes data on the combination of pembrolizumab and regorafenib showed modest activity among patients with advanced hepatocellular carcinoma who had progressed on at least 1 prior immune checkpoint inhibitor...

Anthony El-Khoueiry, MD,...

07/18/2024

Oncology

News

Thermal Ablation Over Surgical Resection for Patients With Smaller Colorectal Liver Metastases

07/18/2024

Allison Casey ;

According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.

According to the phase 3...

07/18/2024

IO Learning

Conference Coverage

Teclistamab Plus Daratumumab and Lenalidomide Show Manageable Safety, Early Efficacy as Frontline Therapy for Patients With Transplant-Ineligible MM

07/02/2024

At the 2024 ASCO Annual Meeting,...

07/02/2024

Oncology

Conference Coverage

Nivolumab Plus Ipilimumab As Potential New Frontline Option for Patients With Unresectable Hepatocellular Carcinoma

07/02/2024

Peter Galle, MD, PhD, discussed...

07/02/2024

Oncology

Conference Coverage

Neoadjuvant Dostarlimab for Patients With Locally Advanced Mismatch Repair Deficient Rectal Cancer

07/01/2024

Andrea Cercek, MD, discussed results from a phase 2 study which demonstrated durable recurrence-free with neoadjuvant dostarlimab among patients with locally advanced mismatch repair deficient rectal cancer.

Andrea Cercek, MD, discussed...

07/01/2024

Oncology

Conference Coverage

Gemcitabine and Nab-Paclitaxel vs 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Metastatic Pancreatic Ductal Adenocarcinoma

06/28/2024

Efrat Dotan, MD, discussed results from the phase 2 GIANT study which compared gemcitabine and nab-paclitaxel to 5-fluorouracil, leucovorin, and liposomal irinotecan among older adults with treatment-naive metastatic pancreatic cancer.

Efrat Dotan, MD, discussed...

06/28/2024

Oncology

Conference Coverage

Ibrutinib Plus Venetoclax Demonstrates Efficacy, Safety for TP53-Mutated Mantle Cell Lymphoma Treatment

06/28/2024

At the 2024 ASCO Annual Meeting, Michael Wang, MD, presents data from the SYMPATICO trail on the encouraging efficacy and safety of ibrutinib plus venetoclax for patients with high-risk TP53-mutated mantle cell lymphoma.

At the 2024 ASCO Annual Meeting,...

06/28/2024

Oncology

Conference Coverage

Erdafitinib Shows Promising Clinical Efficacy, Safety Among Pre-Treated Patients With FGFR-Altered Non-Small Cell Lung Cancer

06/26/2024

Stephanie Holland ;

According to results from the phase 2 RAGNAR study, erdafitinib demonstrated promising clinical activity among pre-treated patients with non-small cell lung cancer (NSCLC) harboring pre-specified FGFR alterations.

According to results from the...

06/26/2024

Oncology

Biological Pathway Reviews

Live Meetings

Recent News

News

First-Line Pembrolizumab Plus Chemotherapy Showed Promise Among Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

07/26/2024

Stephanie Holland ;

According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...

According to results from the...

07/26/2024

Oncology

News

Potential for Shorter Monitoring Period for Patients With R/R MM Following CAR-T Therapy

07/26/2024

Amber Denham ;

A shorter monitoring period may be reasonable for patients with relapsed/refractory multiple myeloma who underwent CAR-T therapy following results that suggest a low risk of cytokine release syndrome and immune effector cell-associated...

A shorter monitoring period may...

07/26/2024

Oncology

News

Utilizing T-Cell Assays in Diagnosing Familial Hemophagocytic Lymphohistiocytosis and Defects in Lymphocyte Exocytosis

07/25/2024

Amber Denham ;

According to a prospective analysis, a combined use of TCR-triggered T-cell and FcR-triggered NK-cell exocytosis assays demonstrated efficacy in diagnosing familial hemophagocytic lymphohistiocytosis and defects in lymphocyte exocytosis.

According to a prospective...

07/25/2024

Oncology

News

SHR-A1811 Showed Promise Among Patients With HER2-Expressing Solid Tumors

07/25/2024

Stephanie Holland ;

According to results from a first-in-human, phase 1 study, SHR-A1811 demonstrated promising antitumor activity with acceptable safety and tolerability among heavily pretreated patients with HER2-expressing or mutated advanced solid tumors.

According to results from a...

07/25/2024

Oncology

News

Brentuximab Vedotin and Ibrutinib Combination Fails to Provide Safety Among Patients With R/R Hodgkin Lymphoma

07/23/2024

Amber Denham ;

According to results from a phase 2 trial, brentuximab vedotin and ibrutinib therapy demonstrated activity among patients with R/R Hodgkin lymphoma, however the combination cannot be recommended for future therapeutic development due to...

According to results from a...

07/23/2024

Oncology

News

Combined Low-Dose Ruxolitinib and Emapalumab Treatment Demonstrates Efficacy for Patients With Hemophagocytic Lymphohistiocytosis

07/23/2024

Gina Tomaine ;

The combination of low-dose ruxolitinib and anti-interferon-gamma antibody emapalumab demonstrated efficacy and safety for treating patients with hemophagocytic lymphohistiocytosis, according to a retrospective analysis.

The combination of low-dose...

07/23/2024

Oncology

News

Analyzing Real-World Outcomes of Emapalumab Treatment for Patients With Primary Hemophagocytic Lymphohistiocytosis

07/23/2024

Gina Tomaine ;

According to retrospective study REAL-HLH, the real-world clinical efficacy, patterns, and survival outcomes of emapalumab treatment among patients with primary hemophagocytic lymphohistiocytosis were consistent with the results a pivotal...

According to retrospective study...

07/23/2024

Oncology

News

Maintenance Selinexor Showed Promise for Patients With Advanced or First-Line Recurrent TP53 Wild-Type Endometrial Cancer

07/23/2024

Stephanie Holland ;

Subgroup analysis results from the phase 3 SIENDO study found selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer.

Subgroup analysis results from...

07/23/2024

Oncology

News

Dostarlimab Plus Chemotherapy as New Standard of Care for Patients With Primary Advanced or Recurrent Endometrial Cancer

07/22/2024

Stephanie Holland ;

Second interim analysis results from the phase 3 RUBY trial demonstrated that the addition of dostarlimab to chemotherapy improved overall survival among patients with primary advanced or recurrent endometrial cancer.

Second interim analysis results...

07/22/2024

Oncology

News

First-Line Amivantamab Plus Lazertinib Superior to Osimertinib Among Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

07/18/2024

Stephanie Holland ;

Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.

Results from the phase 3...

07/18/2024

Oncology